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Abstract
L-Arginine is considered as a non-essential amino acid for most adult mammalian species, but it is
classiﬁed as essential for birds, ﬁsh, possibly reptiles and also for strict carnivores. The product subject
of this assessment is L-arginine produced by fermentation with a genetically modiﬁed strain of
Corynebacterium glutamicum (KCCM 80099). It is intended to be used in feed and water for drinking
for all animal species and categories. The following conclusions refer to the additive ‘L-arginine
produced by Corynebacterium glutamicum KCCM 80099’. Neither the genetically modiﬁed production
strain nor its recombinant DNA were detected in the ﬁnal product. The additive does not give rise to
safety concerns with regard to the genetic modiﬁcation of the production strain. The use of the
additive is safe for target species when supplemented to diets in appropriate amounts, for the
consumer and for the environment. The additive is not hazardous by inhalation, is not a skin sensitiser,
but is corrosive to skin and eyes. The additive is an effective source of arginine for all species. For the
supplemental L-arginine to be as efﬁcacious in ruminants as in non-ruminant species, it requires
protection against microbial degradation in the rumen.
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Summary
Following a request from the European Commission, the Panel on Additives and Products or
Substances used in Animal Feed (FEEDAP) was asked to deliver a scientiﬁc opinion on L-arginine
produced by fermentation with Corynebacterium glutamicum KCCM 80099 when used as nutritional
additive for all animal species.
The approach followed by the FEEDAP Panel to assess the safety and the efﬁcacy of L-threonine
was in line with the principles laid down in Regulation (EC) No 429/2008 and the relevant EFSA
guidance documents. The FEEDAP Panel used the data provided by the applicant together with data
from other sources, such as previous risk assessments by EFSA or other expert bodies, peer-reviewed
scientiﬁc papers, other scientiﬁc reports and experts’ knowledge, to deliver the present output.
L-Arginine is considered as a non-essential amino acid for most adult mammalian species, but it is
classiﬁed as essential for birds, ﬁsh, possibly reptiles and also for strict carnivores.
Neither the genetically modiﬁed production strain nor its recombinant DNA were detected in the
ﬁnal product. The additive L-Arginine, manufactured using the production strain C. glutamicum
KCCM 80099, does not give rise to safety concerns with regard to the genetic modiﬁcation of the
production strain.
The use of the additive is safe for target species when supplemented to diets in appropriate
amounts, for the consumer and the environment.
The product L-arginine produced by C. glutamicum KCCM 80099 is corrosive to skin and eyes but is
not a skin sensitiser. There is a potential for user exposure by inhalation, however, an acute inhalation
toxicity test did not indicate a hazard by inhalation when handling the additive.
The additive is an effective source of arginine for all species. For the supplemental L-arginine to be
as efﬁcacious in ruminants as in non-ruminant species, it requires protection against microbial
degradation in the rumen.
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1. Introduction
1.1. Background and Terms of Reference
Regulation (EC) No 1831/20031 establishes the rules governing the Community authorisation of
additives for use in animal nutrition. In particular, Article 4(1) of that Regulation lays down that any
person seeking authorisation for a feed additive or for a new use of a feed additive shall submit an
application in accordance with Article 7.
The European Commission received a request from CJ Europe GmbH2 for authorisation of the
product L-arginine (L-arginine feed grade) produced by fermentation with Corynebacterium glutamicum
KCCM 80099, when used as a feed additive for all animal species (category: nutritional additives;
functional group: amino acids, their salts and analogues).
According to Article 7(1) of Regulation (EC) No 1831/2003, the Commission forwarded the
application to the European Food Safety Authority (EFSA) as an application under Article 4(1)
(authorisation of a feed additive or new use of a feed additive). The particulars and documents in
support of the application were considered valid by EFSA as of 2 August 2016.
According to Article 8 of Regulation (EC) No 1831/2003, EFSA, after verifying the particulars and
documents submitted by the applicant, shall undertake an assessment in order to determine whether
the feed additive complies with the conditions laid down in Article 5. EFSA shall deliver an opinion on
the safety for the target animals, consumer, user and the environment and on the efﬁcacy of the
product L-arginine (L-arginine feed grade), when used under the proposed conditions of use (see
Section 3.1.7).
1.2. Additional information
The product L-arginine produced by the genetically modiﬁed strain of C. glutamicum KCCM 80099
has not been previously authorised as a feed additive in the European Union (EU). C. glutamicum is
considered by EFSA to be suitable for the Qualiﬁed Presumption of Safety (QPS) approach to safety
assessment when used for amino acid production, provided the susceptibility to antimicrobials has
been demonstrated (EFSA, 2007; EFSA BIOHAZ Panel, 2013, 2017).
L-Arginine (98%) produced by C. glutamicum ATCC 13870 or by C. glutamicum KCTC 10423BP is
currently authorised as a nutritional feed additive for all animals without any restrictions by Commission
Regulation (EC) No 1139/20073 and Commission implementing Regulation (EU) 2016/9724, respectively.
The EFSA Scientiﬁc Panel on Additives and Products or Substances used in Animal Feed (FEEDAP)
issued two opinions on the safety and efﬁcacy of the product containing L-arginine produced by
fermentation using C. glutamicum (ATCC 13870 and KCTC 10423BP, respectively) for all animal species
(EFSA Feedap Panel, 2007, 2016). The FEEDAP Panel issued one opinion on the safety and efﬁcacy of
the use of amino acids (chemical group 34) when used as ﬂavourings for all animal species (EFSA
FEEDAP Panel, 2014).
The EU Scientiﬁc Committee for Food (SCF) found acceptable the use of L-arginine as a food for
particular nutritional purposes (European Commission, 1999). The Joint FAO/Who Expert Committee on
Food Additives (JECFA) issued an opinion on the safety evaluation of certain food additives prepared
by the sixty-third meeting of this committee (WHO, 2006) that included L-arginine.
The EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA Panel) delivered two opinions
related to the substantiation of health claims related to L-arginine (EFSA NDA Panel, 2011a,b).
L-Arginine like other amino acids and other nitrogen compounds is authorised according to
Commission Regulation (EC) No 1243/2008 for infant formulae and follow-on formulae.5 According to
Commission Regulation (EC) No 953/2009 and Commission Directive 2001/15/EC, amino acids such as
L-arginine may be added in all dietary foods for particular nutritional uses including foods for particular
1 Regulation (EC) No 1831/2003 of the European Parliament and of the Council of 22 September 2003 on additives for use in
animal nutrition. OJ L 268, 18.10.2003, p. 29.
2 CJ Europe GmbH, Ober der Roeth 4, 65824, Schwalbach am Taunus. Germany.
3 Commission Regulation (EC) No 1139/2007 of 1 October 2007 concerning the authorisation of L-arginine as a feed additive. OJ
L 256, 11, 2.10.2007, p. 3.
4 Commission Implementing regulation (EU) 2016/972 of 17 June 2016 concerning the authorisation of L-arginine produced by
Corynebacterium glutamicum KCTC 10423BP as feed additive for all animal species. OJ L 161/18, 18.6.2016, p. 3.
5 Commission Regulation (EC) No 1243/2008 of 12 December 2008 amending Annexes III and VI to Directive 2006/141/EC as
regards compositional requirements for certain infant formulae. OJ L 335 25, 13.12.2008, p. 18.
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nutritional uses intended for special medical purposes.6 L-Arginine and related compounds are also
registered as an ingredient in cosmetic products (Commission Decision 2006/257/EEC).7 L-Arginine is
registered as pharmaceutical grade (for total parenteral nutrition) in many European countries and is
described in a monograph of the European Pharmacopoeia (European Pharmacopoeia, 2014).
According to Commission Regulation (EEC) 2377/90, L-arginine is also listed as pharmacologically active
substance in veterinary medicinal products and is not subjected to maximum residue levels when used
in food producing animals.8
2. Data and methodologies
2.1. Data
The present assessment is based on data submitted by the applicant in the form of a technical
dossier9 in support of the authorisation request for the use of L-arginine produced by C. glutamicum
KCCM 80099 as an additive in feed and in water for drinking. The technical dossier was prepared
following the provisions of Article 7 of Regulation (EC) No 1831/2003, Regulation (EC) No 429/200810
and the applicable EFSA guidance documents.
The FEEDAP Panel used the data provided by the applicant together with data from other sources,
such as previous risk assessments by EFSA or other expert bodies, peer-reviewed scientiﬁc papers,
other scientiﬁc reports and experts’ knowledge, to deliver the present output.
EFSA has veriﬁed the European Union Reference Laboratory (EURL) report as it relates to the
methods used for the control of L-arginine in animal feed. The Executive Summary of the EURL report
can be found in Annex A.11
2.2. Methodologies
The approach followed by the FEEDAP Panel to assess the safety and the efﬁcacy of L-arginine
produced by C. glutamicum KCCM 80099 is in line with the principles laid down in Regulation (EC)
No 429/2008 and the relevant guidance documents: Guidance on nutritional additives (EFSA FEEDAP
Panel, 2012a), Guidance on studies concerning the safety of use of the additive for users/workers
(EFSA FEEDAP Panel, 2012b), Technical Guidance: Microbial Studies (EFSA FEEDAP Panel, 2008),
Guidance on the assessment of bacterial susceptibility to antimicrobials of human and veterinary
importance (EFSA FEEDAP Panel, 2012c), Guidance for the preparation of dossiers for additives already
authorised for use in food (EFSA FEEDAP Panel, 2012d), Guidance for establishing the safety of
additives for the consumer (EFSA FEEDAP Panel, 2012e) and Guidance on the risk assessment of
genetically modiﬁed microorganisms and their products intended for food and feed use (EFSA GMO
Panel, 2011).
3. Assessment
The applicant has requested authorisation for the product L-arginine produced by C. glutamicum
KCCM 80099 as an additive in feed and water for drinking for all animal species. L-Arginine is
considered as a non-essential amino acid for most adult mammalian species including humans, but it is
classiﬁed as essential for birds, ﬁsh, possibly reptiles and also for strict carnivores. For mammalian
neonates, it is also considered to be essential.
6 Commission Directive 2001/15/EC of 15 February 2001 on substances that may be added for speciﬁc nutritional purposes in
foods for particular nutritional uses. OJ L 52, 22.2.2001, pp. 19–25. Commission Regulation (EC) No 953/2009 of 13 October
2009 on substances that may be added for speciﬁc nutritional purposes in foods for particular nutritional uses. OJ L 269 9,
14.10.2009, 11 pp.
7 Commission Decision of 9 February 2006 amending Decision 96/335/EC establishing an inventory and a common
nomenclature of ingredients employed in cosmetic products. OJ L 97, 5.4.2006, pp. 1–528.
8 Commission Regulation (EC) No 1931/1999, amending Annexes I, II and III of Council Regulation (EEC) No 2377/90 laying
down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs
of animal origin. OJ L 240, 10.9.1999, pp. 3–10.
9 FEED dossier reference: FAD-2016-0037.
10 Commission Regulation (EC) No 429/2008 of 25 April 2008 on detailed rules for the implementation of Regulation (EC)
No 1831/2003 of the European Parliament and of the Council as regards the preparation and the presentation of applications
and the assessment and the authorisation of feed additives. OJ L 133, 22.5.2008, p. 1.
11 The full report is available on the EURL website: https://ec.europa.eu/jrc/sites/jrcsh/files/ﬁnrep_fad-2016-0037_arginine.pdf
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3.1. Characterisation
3.1.1. Characterisation of the active substance
L-Arginine (International Union of Pure and Applied Chemistry (IUPAC) name: (S)-2-amino-5-
guanidinopentanoic acid; synonym 2-amino-5-guanidinovaleric acid, a compound identiﬁed with the
Chemical Abstracts Service (CAS) No 74-79-3, and the European Inventory of Existing Commercial
chemical Substances (EINECS) No 200-811-1). It has a molecular mass of 174.2 Da. The molecular
formula of L-arginine is C6H14N4O2. The structural formula is given in Figure 1.
3.1.2. Characterisation of the production organism12
The additive is produced by a genetically modiﬁed strain of C. glutamicum, which is deposited in
the Korean Culture Centre of Microorganisms with accession number KCCM 80099.13 The identity of
the strain as belonging to C. glutamicum species was sufﬁciently demonstrated.14
C. glutamicum KCCM 80099 was tested for antibiotic susceptibility using broth microdilution. The
battery of antibiotics tested was that recommended by EFSA (EFSA FEEDAP Panel, 2012c) for ‘Other
Gram +’.15 All minimum inhibitory concentration (MIC) values were equal to or below the corresponding
cut-off values deﬁned by the FEEDAP Panel, except for clindamycin which was exceeded by two dilutions
(1 mg/L vs 0.25 mg/L). No clindamycin MIC distribution is available in the literature for C. glutamicum
that would enable a calculation of a cut-off value. The limited evidence comes from the literature, in
which several Corynebacterium species (but not C. glutamicum) and strains showed a wide MIC range
suggesting that resistant strains have a high MIC value. Thus C. glutamicum KCCM 80099 with a slightly
elevated MIC (1 mg/L vs 0.25 mg/L) can be considered to represent the susceptible population of this
species.
3.1.2.1. Information relating to the genetically modiﬁed microorganism
The parental microorganism and the donor organism are sufﬁciently characterised. The genetic
modiﬁcation process is adequately explained. Uncertainty remains on the possible presence of an
antimicrobial resistance gene in the genome of the production strain, although its absence can be
reasonably expected.16,17,18,19
3.1.3. Manufacturing process20
L-Arginine is produced by fermentation using C. glutamicum KCCM 80099. After fermentation, the
resulting broth is inactivated, the biomass is separated and the arginine is puriﬁed.21,22
Figure 1: Molecular structure of L-arginine
12 This section has been amended following the provisions of Article 8(6) and Article 18 of Regulation (EC) No 1831/2003.
13 Technical dossier/Section II/Annex_CONFID_II_2_06.
14 Technical dossier/Section II/Annex_CONFID_II_2_02.
15 Technical dossier/Section II/Supplementary information October 2016/Annex Q.1.
16 Technical dossier/Section II/Annex_CONFID_II_2_04.
17 Technical dossier/Section II/Supplementary information December 2016.
18 Technical dossier/Section II/Annex_CONFID_II_2_07.
19 Technical dossier/Section II/Annex_CONFID_II_2_05.
20 This section has been amended following the provisions of Article 8(6) and Article 18 of Regulation (EC) No 1831/2003.
21 Technical dossier/Section II.3.1.
22 Technical dossier/Section II/Annex II.3.12.
L-Arginine produced by Corynebacterium glutamicum for all animal species
www.efsa.europa.eu/efsajournal 7 EFSA Journal 2017;15(6):4858
3.1.4. Characterisation of the additive23
According to the speciﬁcation, the additive contains ≥ 98% L-arginine on dry matter basis, ≤ 0.5%
water and ≤ 0.1% ash. The analysis of ﬁve batches showed an average value of L-arginine of 99.6%
on dry matter basis (range 99.4–99.7%).24 Moisture average was 0.48% (range 0.42–0.54%) and
residue on ignition 0.04% (range 0.02–0.06%). Consequently, the amount of unidentiﬁed material is
below 0.1% on a dry matter basis. Analytical data on speciﬁc optical rotation of ﬁve batches showed
an average value of + 27.4° (range + 27.4° to + 27.5°), which is within the range described in the
European Pharmacopoeia for this amino acid.25
3.1.4.1. Impurities
Three batches were analysed for impurities.26 Cadmium, lead and arsenic were below the limit of
detection (LOD),27 whereas mercury ranged from 0.034 to 0.048 mg/kg. Dioxins and dioxin-like PCBs
were < LOD.28 Regarding the microbial contamination, Salmonella spp. (tested in 25 g sample)29 were
negative and total bacterial counts, Escherichia coli, yeasts and ﬁlamentous fungi were < 102 CFU/g.
With respect to the mycotoxins, aﬂatoxins ranged from < 0.05 (LOD) to 0.5 lg/kg, ochratoxin was
< 1 lg/kg, deoxynivalenol < 100 lg/kg and zearalenone < 17 lg/kg. The concentrations of these
impurities do not represent a safety concern.
No viable cells of the production strain were found in three batches of the product (each tested in
triplicate).30,31
No recombinant DNA was detected in three batches of L-Arginine.32,33
3.1.4.2. Physicochemical characteristics
The additive is a white odourless crystalline powder,34 with a bulk density of 400–600 kg/m3 and a
solubility in water (at 25°C) of 50–60 g/L.35 pH value (10% solution) ranged from 11.7 to 11.8 in ﬁve
batches tested.22
The particle size distribution (three batches of the additive) was analysed by laser-diffraction
technique. The fraction < 10 lm ranged from 2.6% to 3.1% (v/v), the fraction < 50 lm ranged from
11.4% to 13.9% (v/v) and the fraction < 100 lm ranged from 25.9% to 30.2% (v/v).36 The dusting
potential of three batches of the ﬁnal product (Stauber–Heubach method) ranged from 2.1 to 2.6 g/m3.37
3.1.5. Stability and homogeneity
The shelf life of the additive (three batches) was studied when stored in sealed brown glass
containers at 25 for 12 months or 40°C for 6 months. The losses detected at the end of the respective
storage periods ranged from 0% to 0.8% at 25°C and from 0.2% to 0.7% at 40°C.38
The stability of the additive (three batches) was studied in a vitamin/mineral premixture (with
choline chloride (80 g/kg)) when stored in sealed brown glass containers at 25°C or 40°C for
6 months.39 L-Arginine was added at a concentration of 5%. The losses observed at the end of the
storage period ranged from 15% to 17% at 25°C and from 25% to 33% at 40°C.
23 This section has been amended following the provisions of Article 8(6) and Article 18 of Regulation (EC) No 1831/2003.
24 Technical dossier/Section II/Annex II.1.4. Method according to the EU ofﬁcial method (Regulation (EC) 152/2009) for
determination of amino acids.
25 Technical dossier/Section II/Annex II.1.2.
26 Technical dossier/Section II/Annex II.1.5.
27 LOD in mg/kg was 1 for arsenic and lead and 0.1 for cadmium.
28 LOD of PCDD/F (in ng/kg) ranged from 0.02 to 1 and that of PCBs ranged from 0.5 to 20 depending on the substance
analysed.
29 Technical dossier/Supplementary information December 2016/Response to question 2.
30 Technical dossier/Section II/Annex_CONFID_II_2_08.
31 Technical dossier/Section II/Supplementary information December 2016 /Annex Q5.
32 Technical dossier/Section II/Annex_CONFID_II_2_09.
33 Technical dossier/Section II/Supplementary information December 2016 /Annex Q6.
34 Technical dossier/Section II/Annex II.3.1.
35 Technical dossier/Section II.1.5.
36 Technical dossier/Section II/Annex II.1.6.
37 Technical dossier/Section II/Annex II.1.7.
38 Technical dossier/Section II/Annex II.4.1. Method according to the EU ofﬁcial method (Reg EC 152/2009).
39 Technical dossier/Section II/Annexes II.4.2 and II.4.4. Method according to the EU ofﬁcial method (Reg EC 152/2009).
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The stability of the additive (three batches) was studied in three different compound feeds (mash
or pelleted feed for pigs for fattening, laying hens and chickens for fattening) when supplemented at
0.2%.40 The basal diets consisted of maize, wheat and soybean meal in the case of laying hens and
chickens for fattening; and of barley, maize and soybean meal in the case of the pigs for fattening.
The diets contained about 1,000 mg choline chloride/kg feed. Pelleting was performed at 60°C and
2.35 bar for 8 s and the only loss observed was 1% in one of the three batches studied. The
compound feeds were stored in sealed brown glass containers at 25°C or 40°C for 3 months. No losses
were observed in mash feed or pelleted feed at the end of the storage period.
The stability of the ﬁnal product (three batches) was studied in water for drinking when used at a
concentration of 0.05% and stored at 25°C or 40°C for 48 h. No losses were observed.41
The capacity of the additive to distribute homogeneously in feed (mash and pelleted compound
feeds described above) was studied analysing sets of 10 subsamples. In both cases, mash and
pelleted compound feed, the coefﬁcients of variation ranged from 2% to 4%.42
3.1.6. Physicochemical incompatibilities in feed
No physicochemical incompatibilities in feed are expected with medicinal products or feed materials.
High losses in premixtures indicate incompatibility with one or more constituents of the feed
premixture.
3.1.7. Conditions of use
The current application for L-arginine is as a nutritional additive to feed for all animal species and
categories without maximum content in feed or time of administration. According to the applicant, the
additive can be added directly to compound feedingstuffs or via premixtures or water for drinking.43
No inclusion levels are proposed as the requirements in quantitative terms depend on the species, the
physiological state of the animal, the performance level and the environmental conditions, as well as
the amino acid composition of the unsupplemented diet.
3.2. Safety
3.2.1. Safety of the genetic modiﬁcations44
The recipient organism is considered to be safe. The slightly elevated MIC (1 mg/L vs 0.25 mg/L)
for clindamycin can be considered to represent the susceptible population of this species. The
introduced gene does not trigger a safety concern. No vector sequences are expected to remain in the
ﬁnal production strain.
Although uncertainty remains on the possible presence of an antimicrobial resistance gene in the
production strain, neither the genetically modiﬁed production strain nor its recombinant DNA was
detected in the ﬁnal product. Therefore, the additive does not give rise to safety concerns with regard
to the genetic modiﬁcation of the production strain.
3.2.2. Safety for the target species
Tolerance studies with essential and conditionally essential amino acids cannot be designed in
accordance with the protocols of conventional toxicity experiments because high dietary concentrations
of a certain amino acid will result in amino acid imbalances and depression of feed intake and, hence,
impaired performance. This statement is, in principle, also applicable to non-essential amino acids
since a well-balanced dietary protein should have a certain ratio between essential and non essential
amino acids for optimal performance and low nitrogen emissions per product (Baker, 2004).
Nevertheless, for nutritional additives produced by fermentation, the risks associated with the residues
of the fermentation process in the ﬁnal product need to be assessed. In this speciﬁc product, the
amount of identiﬁed material represents > 99.9% on a dry matter basis. Therefore, the FEEDAP
40 Technical dossier/Section II/Annex II.4.3 and Supplementary information December 2016/Annex Q3 and Response to question
3. Method according to the EU ofﬁcial method (Reg EC 152/2009).
41 Technical dossier/Section II/Annex II.4.5.
42 Technical dossier/Section II/Annex II.4.6.
43 Technical dossier/Section II.5.1.
44 This section has been amended following the provisions of Article 8(6) and Article 18 of Regulation (EC) No 1831/2003.
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Panel considers that safety concerns for target species are highly unlikely to arise from L-arginine
produced by C. glutamicum KCCM 80099.
The classiﬁcation of L-arginine as a dispensable or an indispensable amino acid, its dietary
requirements, the adverse effects of excess of arginine in the diets and the lysine-arginine antagonism
have been discussed in a previous opinion (EFSA FEEDAP Panel, 2016). In that opinion, it was
reported that feeding weaned piglets (age: 3–4 weeks; live weight 7 kg) in short-term experiments
(3–4 weeks) with 0.67%, 1.6% and 2.0% supplemental L-arginine decreased weight gain and feed
intake, but had variable effects on feed/gain and no effect on the nitrogen balance (Southern and
Baker, 1982; Anderson et al., 1984), whereas a moderate L-arginine supplementation (0.22%) did not
affect performance of growing piglets (Rosell and Zimmerman, 1985). More recent research (Hu et al.,
2015; Wu et al., 2016), however, revealed a higher tolerance to L-arginine in pig diets. The authors
assessed the safety of long-term L-arginine supplementation (0%, 1%, 1.5% and 2%) to a typical
maize-soybean meal diet (1.35% arginine as background) in pigs between 30 and 121 days of age,
based on general observations (e.g. behaviour, skin health, and hair appearance), feed intake, growth,
body composition, as well as haematological and blood chemistry measurements. Results of all of the
measured variables in the pigs were within physiological ranges and were not adversely affected by
the L-arginine supplementation.
The initial products of L-arginine degradation by ruminal microorganisms are ornithine, d-
aminovaleric acid and putrescine (Lewis and Emery, 1962), which are then either converted to volatile
fatty acids or incorporated into microbial cell biomass. As these products have no recorded deleterious
effects to the host animal, there are no safety concerns arising from ruminal L-arginine metabolism
when supplemented to diets in appropriate amounts.
The FEEDAP Panel, in its previous statement (EFSA FEEDAP Panel, 2010), identiﬁed risks of
nutritional imbalances and hygienic concerns in amino acids when administered in water for drinking.
3.2.2.1. Conclusions on safety for the target species
The use of L-arginine produced by C. glutamicum KCCM 80099 is safe for target species when
supplemented to diets in appropriate amounts. There are no safety concerns arising from ruminal
L-arginine metabolism.
3.2.3. Safety for the consumer
The absorption and metabolic fate of arginine were described in a previous opinion (EFSA, 2007).
As a general principle, conventional toxicology studies are considered to be inappropriate for amino
acids.
The product under assessment is produced by fermentation. Concerns for the consumer would
derive not from the amino acid itself, which will be incorporated into animal protein, but from possible
residues from the fermentation. Considering that the additive is highly puriﬁed (≥ 99.9% L-arginine on
dry matter basis), no additional toxicological data are required (EFSA FEEDAP Panel, 2012).
Amino acids supplemented to feed will be incorporated into proteins of tissues and/or products of
target animal species and any of their potential excess will be metabolised and excreted. Therefore,
the composition of tissues and products of animal origin will not be changed by the use of L-arginine in
animal nutrition.
3.2.3.1. Conclusions on safety for the consumer
The composition of edible tissues and products of animal origin will not be changed by the use of
L-arginine in animal nutrition. Considering the high purity of the product under assessment, no risks
are expected for the consumer from the use of L-arginine produced by C. glutamicum KCCM 80099 as
a feed additive.
3.2.4. Safety for the user
The test item tested in the submitted toxicological studies was the product under assessment
(99.1% purity on ‘as is’ basis).
3.2.4.1. Effects on the respiratory system
The portion of particles having a diameter smaller than 100, 50 and 10 lm is about 30%, 14% and
3% (v/v), respectively. The dusting potential is up to 2.6 g/m3, indicating that exposure by inhalation
of the user is likely (see Section 3.1.4).
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An acute inhalation test was carried out on RccHanTM:WIST rats (ﬁve males and ﬁve females) in
accordance with OECD guideline 403.45 The adverse effects seen after 4 h exposure at the dose of
5.1 g L-arginine/m3 were decreased respiratory rate, hunched posture, piloerection and wet fur, but
the animals recovered to normality from days 2 to 4 post exposure. No mortality occurred in the
following 2 weeks and no pathological ﬁndings were noted at necropsy. Although transient adverse
effects were observed at an exposure twofold the maximum dusting potential measured in the
additive, they do not indicate a hazard by inhalation when handling the additive.
3.2.4.2. Effects on skin and eyes
The product under assessment has a high pH (11.8) in aqueous solution.
An in vitro study (skin corrosion: transcutaneous electrical resistance test) was carried out
according to OECD guideline 430.46 The mean transcutaneous electrical resistance value recorded for
the 24 h contact period was 3.3 kO. This result indicates that the L-arginine under assessment has the
potential to cause skin corrosion in vivo.
As the product is corrosive for the skin, it is also considered corrosive for the eye.
A local lymph node assay (LLNA) was performed using female CBA/Ca mice, in accordance with
OECD Guideline 429.47 The concentration at which no toxic signs were observed (10%) was selected
in a preliminary screening test and used as the highest dose investigated in the LLNA. Three groups
(4 mice/group) were treated with 50 lL (25 lL per ear) of the test item as a solution 1% in distilled
water at concentrations of 10%, 5% and 2.5% (w/w). A further group of four animals (control) was
treated with the diluent alone (1% test item in distilled water). The proliferation response of lymph
node cells was expressed as the ratio of 3H-thymidine incorporation into lymph node cells of test nodes
relative to that recorded for the control nodes (stimulation index). No proliferation response was
elicited by the treatment. No clinical signs, mortality or changes in body weight were observed. The
product under assessment is not considered a skin sensitiser.
3.2.4.3. Conclusions on safety for the user
The product L-arginine produced by C. glutamicum KCCM 80099 is corrosive to skin and eyes but is
not a skin sensitiser. There is a potential for user exposure by inhalation, however, an acute inhalation
toxicity test did not indicate a hazard by inhalation when handling the additive.
3.2.5. Safety for the environment48
L-Arginine is a natural component of animals and plants whose use in animal nutrition would not
lead to any localised increase of its concentration in the environment. It is mainly not excreted as
such, but as urea or uric acid and carbon dioxide. The FEEDAP Panel concludes that the use of the
product L-arginine produced by C. glutamicum KCCM 80099 in animal nutrition would not pose a risk
to the environment.
Although uncertainty remains on the possible presence of an antimicrobial resistance gene in the
production strain, neither the genetically modiﬁed production strain nor its recombinant DNA was
detected in the ﬁnal product. Therefore, the additive does not give rise to environmental safety
concerns with regard to the genetic modiﬁcation of the production strain.
3.3. Efﬁcacy
Efﬁcacy studies are not required for amino acids naturally occurring in proteins of plants and
animals. The nutritional role of the amino acid L-arginine is well established in the scientiﬁc literature
(Schuhmacher, 2002).
In beef or dairy cattle fed a variety of diets, L-arginine has not been identiﬁed to be limiting
(Schwab et al., 2005). The rapid degradation of L-arginine by ruminal microorganisms has been
described in a previous opinion (EFSA FEEDAP Panel, 2016). Consequently, for the supplemental
L-arginine to be as efﬁcacious in ruminants as in non-ruminant species, it requires protection against
degradation in the rumen.
45 Technical dossier/Section III/Annex III.3.2.
46 Technical dossier/Section III/Annex III.3.3.
47 Technical dossier/Section III/Annex III.3.4.
48 This section has been amended following the provisions of Article 8(6) and Article 18 of Regulation (EC) No 1831/2003.
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3.4. Post-market monitoring
The FEEDAP Panel considers that there is no need for speciﬁc requirements for a post-market
monitoring plan other than those established in the Feed Hygiene Regulation49 and Good
Manufacturing Practice.
4. Conclusions
Neither the genetically modiﬁed production strain nor its recombinant DNA were detected in the
ﬁnal product. The additive L-Arginine, manufactured using the production strain C. glutamicum
KCCM 80099, does not give rise to safety concerns with regard to the genetic modiﬁcation of the
production strain.
The use of the additive is safe for target species when supplemented to diets in appropriate
amounts, for the consumer and the environment.
The additive is not hazardous by inhalation, is not a skin sensitiser, but is corrosive to skin and
eyes.
The additive is an effective source of arginine for all species. For the supplemental L-arginine to be
as efﬁcacious in ruminants as in non-ruminant species, it requires protection against microbial
degradation in the rumen.
5. Recommendations
The description of the additive should contain the statement ‘L-arginine produced by
Corynebacterium glutamicum KCCM 800990.
Documentation provided to EFSA
1) L-Arginine, feed grade, produced by C. glutamicum KCCM 80099. August 2016. Submitted by
CJ Europe GmbH.
2) L-Arginine, feed grade, produced by C. glutamicum KCCM 80099. Supplementary
information. December 2016. Submitted by CJ Europe GmbH.
3) Evaluation report of the European Union Reference Laboratory for Feed Additives on the
Methods(s) of Analysis for L-Arginine, feed grade, produced by C. glutamicum KCCM 80099.
4) Comments from Member States.
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Annex A – Evaluation report of the European Reference Laboratory on the
analytical methods submitted in connexion with the application for
authorisation of L-arginine produced by Corynebacterium glutamicum
KCCM 80099
In the current application, authorisation is sought under Article 4(1) for L-arginine produced by
fermentation with Corynebacterium glutamicum KCCM 80099, under the category/functional group 3
(c) ‘nutritional additives’/‘amino acids, their salts and analogues’, according to Annex I of Regulation
(EC) No 1831/2003. Authorisation is sought for all animal species. L-Arginine is already authorised as
feed additive under Commission Regulation (EC) No 1139/2007 and Commission Implementing
Regulation (EU) 2016/972.
For the quantiﬁcation of L-arginine in feed additive, premixtures and feedingstuffs, the Applicant
submitted the ring-trial validated community method (Commission Regulation (EC) No 152/2009). The
method was further ring-trial validated by CEN resulting in EN ISO 13903:2005. The method is based
on ion exchange chromatography coupled with post-column derivatisation and photometric detection
(IEC-VIS). This method does not distinguish between the salts and the amino acid enantiomers, and it
is designed for feedingstuffs and premixtures. The following performance characteristics were reported
for the quantiﬁcation of total arginine: a relative standard deviation for repeatability (RSDr) ranging
from 2.3% to 3.3% and a relative standard deviation for reproducibility (RSDR) ranging from 7.2% to
9.7%.
In addition, the EURL identiﬁed the ‘L-arginine monograph’ of the Food Chemical Codex (FCC) for
the characterisation of the feed additive. Since the Applicant provided no experimental data to
determine arginine in water, the EURL is neither able to evaluate nor to recommend a method for
ofﬁcial control to determine arginine in water.
Based on the performance characteristics available, the EURL recommends for ofﬁcial control
the community method or the equivalent EN ISO 13903:2005 method based on IEC-VIS for the
quantiﬁcation of arginine in the feed additive, premixtures and feedingstuffs together with the
‘L-arginine monograph’ of the FCC for the characterisation of the feed additive.
Further testing or validation of the methods to be performed through the consortium of National
Reference Laboratories as speciﬁed by Article 10 (Commission Regulation (EC) No 378/2005) is not
considered necessary.
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